WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H124802
CAS#: N/A
Description: CVN417 is a Novel Brain-Penetrant α6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction. CVN417 modulated phasic dopaminergic neurotransmission in an impulse-dependent manner. In a rodent model of resting tremor, CVN417 attenuated this behavioral phenotype. These data suggest that selective antagonism of α6-containing nAChR, with molecules such as CVN417, may have therapeutic utility in treating the movement dysfunctions observed in conditions such as Parkinson’s disease.
Hodoodo Cat#: H124802
Name: CVN417
CAS#: N/A
Chemical Formula: C18H23ClN4O2
Exact Mass: 362.15
Molecular Weight: 362.860
Elemental Analysis: C, 59.58; H, 6.39; Cl, 9.77; N, 15.44; O, 8.82
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: CVN417; CVN-417; CVN 417
IUPAC/Chemical Name: (S)-5-(2-chloro-4-methoxyphenyl)-1-methyl-N-(1-methylpiperidin-3-yl)-1H-pyrazole-3-carboxamide
InChi Key: QLOHOGRMRUDDPM-LBPRGKRZSA-N
InChi Code: InChI=1S/C18H23ClN4O2/c1-22-8-4-5-12(11-22)20-18(24)16-10-17(23(2)21-16)14-7-6-13(25-3)9-15(14)19/h6-7,9-10,12H,4-5,8,11H2,1-3H3,(H,20,24)/t12-/m0/s1
SMILES Code: ClC1=C(C2=CC(C(N[C@@H]3CN(C)CCC3)=O)=NN2C)C=CC(OC)=C1
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 362.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
Christie LA, Brice NL, Rowland A, Dickson L, Anand R, Teall M, Doyle KJ, Narayana L, Mitchell C, Harvey JRM, Mulligan V, Dawson LA, Cragg SJ, Carlton M, Bürli RW. Discovery of CVN417, a Novel Brain-Penetrant α6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction. J Med Chem. 2023 Aug 31. doi: 10.1021/acs.jmedchem.3c00630. Epub ahead of print. PMID: 37651656.